Hudson Bay Capital Management
CRNX icon

Hudson Bay Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Hudson Bay Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-7,500
Closed -$223K – 762
2023
Q3 		$223K Buy
+7,500
New +$155K ﹤0.01% 626

Other funds holding CRNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Hudson Bay Capital Management's CRNX Position: Q4 2023 in Review

Hudson Bay Capital Management sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2023, closing a stake of 7,500 shares — an estimated $223K sold.

Hudson Bay Capital Management first reported a position in CRNX in Q3 2023 and held it in 1 quarter. The position peaked at $223K in Q3 2023. 181 funds tracked by Wall St. Rank hold CRNX as of Q4 2023.

  • Hudson Bay Capital Management reported no remaining Crinetics Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Hudson Bay Capital Management sold 7,500 Crinetics Pharmaceuticals shares in Q4 2023, an estimated $223K.
  • Hudson Bay Capital Management first reported a position in Crinetics Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Hudson Bay Capital Management's Crinetics Pharmaceuticals position peaked at $223K in Q3 2023.
  • 181 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2023.

Based on Hudson Bay Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.